REGENERON PHARMACEUTICALS, INC. Proceeds from Sale and Maturity of Marketable Securities
REGENERON PHARMACEUTICALS, INC. (REGN) reported Proceeds from Sale and Maturity of Marketable Securities of $4.76 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $2.15B, a 0.89% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $2.61B, a 24.63% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $2.56B, a 1.05% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $3.37B, a 20.98% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2025 was $11.55B, a 23.17% decline from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $15.03B, a 59.15% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $9.44B, a 70.11% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $5.55B, a 150.55% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 3 month as first filed | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 6 month as first filed | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 9 month as first filed | Proceeds from Sale and Maturity of Marketable Securities 12 month | Proceeds from Sale and Maturity of Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.15B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $4.76B 10-Q · filed 2026-07-30 | $7.31B derived: sum of 3 quarters · filed 2026-07-30 | $10.68B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $2.61B 10-Q · filed 2026-04-29 | $5.16B derived: sum of 2 quarters · filed 2026-04-29 | $8.53B derived: sum of 3 quarters · filed 2026-04-29 | $10.69B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $2.56B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $5.92B derived: sum of 2 quarters · filed 2026-02-04 | $8.09B derived: sum of 3 quarters · filed 2026-07-30 | $11.55B 10-K · filed 2026-02-04 | ||||
| 2025-09-30 | $3.37B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $5.53B derived: sum of 2 quarters · filed 2026-07-30 | $8.99B 10-Q · filed 2025-10-28 | $11.57B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $2.17B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $5.63B 10-Q · filed 2026-07-30 | $8.21B derived: sum of 3 quarters · filed 2026-07-30 | $12.47B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $3.46B 10-Q · filed 2026-04-29 | $6.04B derived: sum of 2 quarters · filed 2026-04-29 | $10.30B derived: sum of 3 quarters · filed 2026-04-29 | $14.35B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $2.58B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $6.84B derived: sum of 2 quarters · filed 2026-02-04 | $10.90B derived: sum of 3 quarters · filed 2026-02-04 | $15.03B 10-K · filed 2026-02-04 | ||||
| 2024-09-30 | $4.26B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $8.31B derived: sum of 2 quarters · filed 2025-10-28 | $12.45B 10-Q · filed 2025-10-28 | $14.83B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-06-30 | $4.05B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $8.19B 10-Q · filed 2025-08-01 | $10.57B derived: sum of 3 quarters · filed 2026-02-04 | $13.57B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-03-31 | $4.13B 10-Q · filed 2025-04-29 | $6.52B derived: sum of 2 quarters · filed 2026-02-04 | $9.51B derived: sum of 3 quarters · filed 2026-02-04 | $11.78B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2023-12-31 | $2.38B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $5.38B derived: sum of 2 quarters · filed 2026-02-04 | $7.65B derived: sum of 3 quarters · filed 2026-02-04 | $9.44B 10-K · filed 2026-02-04 | ||||
| 2023-09-30 | $3.00B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $5.27B derived: sum of 2 quarters · filed 2024-10-31 | $7.06B 10-Q · filed 2024-10-31 | $8.60B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-06-30 | $2.27B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $4.06B 10-Q · filed 2024-08-01 | $5.60B derived: sum of 3 quarters · filed 2025-02-05 | $7.43B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-03-31 | $1.79B 10-Q · filed 2024-05-02 | $3.33B derived: sum of 2 quarters · filed 2025-02-05 | $5.16B derived: sum of 3 quarters · filed 2025-02-05 | $6.60B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2022-12-31 | $1.54B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $3.37B derived: sum of 2 quarters · filed 2025-02-05 | $4.80B derived: sum of 3 quarters · filed 2025-02-05 | $5.55B 10-K · filed 2025-02-05 | ||||
| 2022-09-30 | $1.83B derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $3.27B derived: sum of 2 quarters · filed 2023-11-02 | $4.01B 10-Q · filed 2023-11-02 | $4.33B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-06-30 | $1.44B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.18B 10-Q · filed 2023-08-03 | $2.50B derived: sum of 3 quarters · filed 2024-02-05 | $3.18B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-03-31 | $746.30M 10-Q · filed 2023-05-04 | $1.06B derived: sum of 2 quarters · filed 2024-02-05 | $1.74B derived: sum of 3 quarters · filed 2024-02-05 | $2.55B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2021-12-31 | $318.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $998.20M derived: sum of 2 quarters · filed 2024-02-05 | $1.80B derived: sum of 3 quarters · filed 2024-02-05 | $2.22B 10-K · filed 2024-02-05 | ||||
| 2021-09-30 | $680.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.48B derived: sum of 2 quarters · filed 2022-11-03 | $1.90B 10-Q · filed 2022-11-03 | $2.35B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-06-30 | $800.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $1.22B 10-Q · filed 2022-08-03 | $1.67B derived: sum of 3 quarters · filed 2023-02-06 | $2.16B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-03-31 | $416.30M 10-Q · filed 2022-05-04 | $871.00M derived: sum of 2 quarters · filed 2023-02-06 | $1.36B derived: sum of 3 quarters · filed 2023-02-06 | $3.76B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2020-12-31 | $454.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $941.30M derived: sum of 2 quarters · filed 2023-02-06 | $3.34B derived: sum of 3 quarters · filed 2023-02-06 | $3.79B 10-K · filed 2023-02-06 | ||||
| 2020-09-30 | $486.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.89B derived: sum of 2 quarters · filed 2021-11-04 | $3.33B 10-Q · filed 2021-11-04 | $3.63B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-06-30 | $2.40B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.84B 10-Q · filed 2021-08-05 | $3.14B derived: sum of 3 quarters · filed 2022-02-07 | $3.70B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-03-31 | $441.20M 10-Q · filed 2021-05-06 | $739.00M derived: sum of 2 quarters · filed 2022-02-07 | $1.30B derived: sum of 3 quarters · filed 2022-02-07 | $1.71B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2019-12-31 | $297.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $858.30M derived: sum of 2 quarters · filed 2022-02-07 | $1.27B derived: sum of 3 quarters · filed 2022-02-07 | $1.60B 10-K · filed 2022-02-07 | ||||
| 2019-09-30 | $560.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $968.00M derived: sum of 2 quarters · filed 2020-11-05 | $1.31B 10-Q · filed 2020-11-05 | $1.44B derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-06-30 | $407.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $745.90M 10-Q · filed 2020-08-05 | $877.40M derived: sum of 3 quarters · filed 2021-02-08 | $1.06B derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-03-31 | $338.40M 10-Q · filed 2020-05-05 | $469.90M derived: sum of 2 quarters · filed 2021-02-08 | $651.80M derived: sum of 3 quarters · filed 2021-02-08 | $858.70M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2018-12-31 | $131.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | $313.40M derived: sum of 2 quarters · filed 2021-02-08 | $520.30M derived: sum of 3 quarters · filed 2021-02-08 | $775.60M 10-K · filed 2021-02-08 | ||||
| 2018-09-30 | $181.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $388.80M derived: sum of 2 quarters · filed 2019-11-05 | $644.10M 10-Q · filed 2019-11-05 | $644.10M 10-Q · filed 2018-11-06 | $809.42M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-06-30 | $206.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $462.20M 10-Q · filed 2019-08-06 | $462.21M 10-Q · filed 2018-08-02 | $627.52M derived: sum of 3 quarters · filed 2020-02-07 | $734.63M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-03-31 | $255.30M 10-Q · filed 2019-05-07 | $255.28M 10-Q · filed 2018-05-03 | $420.63M derived: sum of 2 quarters · filed 2020-02-07 | $527.73M derived: sum of 3 quarters · filed 2020-02-07 | $680.89M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2017-12-31 | $165.32M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $272.43M derived: sum of 2 quarters · filed 2020-02-07 | $425.59M derived: sum of 3 quarters · filed 2020-02-07 | $544.60M 10-K · filed 2020-02-07 | $544.58M 10-K · filed 2018-02-08 | |||
| 2017-09-30 | $107.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $260.26M derived: sum of 2 quarters · filed 2018-11-06 | $379.27M 10-Q · filed 2018-11-06 | $461.68M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-06-30 | $153.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $272.17M 10-Q · filed 2018-08-02 | $354.57M derived: sum of 3 quarters · filed 2019-02-07 | $444.49M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-03-31 | $119.01M 10-Q · filed 2018-05-03 | $201.42M derived: sum of 2 quarters · filed 2019-02-07 | $291.33M derived: sum of 3 quarters · filed 2019-02-07 | $333.10M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2016-12-31 | $82.41M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $172.32M derived: sum of 2 quarters · filed 2019-02-07 | $214.09M derived: sum of 3 quarters · filed 2019-02-07 | $274.50M 10-K · filed 2019-02-07 | $274.46M 10-K · filed 2017-02-09 | |||
| 2016-09-30 | $89.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $131.68M derived: sum of 2 quarters · filed 2017-11-08 | $192.09M 10-Q · filed 2017-11-08 | $253.53M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-06-30 | $41.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $102.18M 10-Q · filed 2017-08-03 | $163.62M derived: sum of 3 quarters · filed 2018-02-08 | $235.84M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-03-31 | $60.41M 10-Q · filed 2017-05-04 | $121.85M derived: sum of 2 quarters · filed 2018-02-08 | $194.08M derived: sum of 3 quarters · filed 2018-02-08 | $307.39M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2015-12-31 | $61.44M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $133.67M derived: sum of 2 quarters · filed 2018-02-08 | $246.98M derived: sum of 3 quarters · filed 2018-02-08 | $327.44M 10-K · filed 2018-02-08 | ||||
| 2015-09-30 | $72.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $185.54M derived: sum of 2 quarters · filed 2016-11-04 | $266.00M 10-Q · filed 2016-11-04 | $525.93M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-06-30 | $113.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $193.77M 10-Q · filed 2016-08-04 | $453.71M derived: sum of 3 quarters · filed 2017-02-09 | $514.34M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-03-31 | $80.46M 10-Q · filed 2016-05-05 | $340.39M derived: sum of 2 quarters · filed 2017-02-09 | $401.02M derived: sum of 3 quarters · filed 2017-02-09 | $474.40M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2014-12-31 | $259.94M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $320.57M derived: sum of 2 quarters · filed 2017-02-09 | $393.95M derived: sum of 3 quarters · filed 2017-02-09 | $476.42M 10-K · filed 2017-02-09 | ||||
| 2014-09-30 | $60.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $134.01M derived: sum of 2 quarters · filed 2015-11-04 | $216.48M 10-Q · filed 2015-11-04 | $275.47M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-06-30 | $73.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $155.85M 10-Q · filed 2015-08-04 | $214.84M derived: sum of 3 quarters · filed 2016-02-11 | $226.75M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-03-31 | $82.47M 10-Q · filed 2015-05-07 | $141.46M derived: sum of 2 quarters · filed 2016-02-11 | $153.37M derived: sum of 3 quarters · filed 2016-02-11 | $405.86M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2013-12-31 | $58.99M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $70.90M derived: sum of 2 quarters · filed 2016-02-11 | $323.39M derived: sum of 3 quarters · filed 2016-02-11 | $378.15M 10-K · filed 2016-02-11 | ||||
| 2013-09-30 | $11.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $264.40M derived: sum of 2 quarters · filed 2014-11-04 | $319.15M 10-Q · filed 2014-11-04 | $497.59M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-06-30 | $252.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $307.24M 10-Q · filed 2014-08-05 | $485.68M derived: sum of 3 quarters · filed 2015-02-12 | $574.57M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-03-31 | $54.75M 10-Q · filed 2014-05-08 | $233.19M derived: sum of 2 quarters · filed 2015-02-12 | $322.08M derived: sum of 3 quarters · filed 2015-02-12 | $418.11M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2012-12-31 | $178.44M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $267.33M derived: sum of 2 quarters · filed 2015-02-12 | $363.36M derived: sum of 3 quarters · filed 2015-02-12 | $439.21M 10-K · filed 2015-02-12 | ||||
| 2012-09-30 | $88.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $184.92M derived: sum of 2 quarters · filed 2013-11-05 | $260.77M 10-Q · filed 2013-11-05 | $362.60M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-06-30 | $96.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $171.88M 10-Q · filed 2013-08-06 | $273.71M derived: sum of 3 quarters · filed 2014-02-13 | $381.61M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-03-31 | $75.85M 10-Q · filed 2013-05-03 | $177.68M derived: sum of 2 quarters · filed 2014-02-13 | $285.58M derived: sum of 3 quarters · filed 2014-02-13 | $444.09M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2011-12-31 | $101.83M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $209.72M derived: sum of 2 quarters · filed 2014-02-13 | $368.24M derived: sum of 3 quarters · filed 2014-02-13 | $426.36M 10-K · filed 2014-02-13 | ||||
| 2011-09-30 | $107.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $266.41M derived: sum of 2 quarters · filed 2012-10-24 | $324.53M 10-Q · filed 2012-10-24 | $369.77M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-06-30 | $158.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $216.63M 10-Q · filed 2012-07-25 | $261.87M derived: sum of 3 quarters · filed 2013-02-15 | $353.64M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-03-31 | $58.12M 10-Q · filed 2012-04-26 | $58.15M 10-Q · filed 2011-05-03 | $103.36M derived: sum of 2 quarters · filed 2013-02-15 | $195.13M derived: sum of 3 quarters · filed 2013-02-15 | $267.91M derived: sum of 4 quarters · filed 2013-02-15 | |||
| 2010-12-31 | $45.24M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $137.01M derived: sum of 2 quarters · filed 2013-02-15 | $209.79M derived: sum of 3 quarters · filed 2013-02-15 | $273.72M 10-K · filed 2013-02-15 | $276.60M 10-K · filed 2011-02-17 | |||
| 2010-09-30 | $91.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $164.55M derived: sum of 2 quarters · filed 2011-10-27 | $228.48M 10-Q · filed 2011-10-27 | $230.51M 10-Q · filed 2010-10-28 | $238.67M derived: sum of 4 quarters · filed 2012-02-21 | |||
| 2010-06-30 | $72.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $136.71M 10-Q · filed 2011-07-28 | $137.91M 10-Q · filed 2010-07-28 | $146.89M derived: sum of 3 quarters · filed 2012-02-21 | $241.10M derived: sum of 4 quarters · filed 2012-02-21 | |||
| 2010-03-31 | $63.94M 10-Q · filed 2011-05-03 | $74.12M derived: sum of 2 quarters · filed 2012-02-21 | $168.33M derived: sum of 3 quarters · filed 2012-02-21 | |||||
| 2009-12-31 | $10.18M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $104.39M derived: sum of 2 quarters · filed 2012-02-21 | $295.12M 10-K · filed 2012-02-21 | $297.41M 10-K · filed 2011-02-17 | ||||
| 2009-09-30 | $94.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $284.93M 10-Q · filed 2010-10-28 | ||||||
| 2009-06-30 | $190.72M 10-Q · filed 2010-07-28 | |||||||
| 2008-12-31 | $646.86M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |